PMID- 8680652
OWN - NLM
STAT- MEDLINE
DCOM- 19960822
LR  - 20210107
IS  - 1067-5582 (Print)
IS  - 1067-5582 (Linking)
VI  - 18
IP  - 4
DP  - 1995 Nov
TI  - HLA associations in the antitumor response against malignant melanoma.
PG  - 242-52
AB  - In this study we analyzed the human leukocyte antigen (HLA) pattern of North 
      American Caucasian patients with metastatic melanoma as compared with the North 
      American Caucasian (NAC) population. We also investigated whether the HLA type of 
      melanoma patients had an effect on their tolerance and response to interleukin-2 
      (IL-2)-based therapy. Four hundred twelve serologic phenotypes of Caucasian 
      melanoma patients referred to the National Cancer Institute, National Institutes 
      of Health, from February 1989 through December 1993 were collected by typing the 
      patient's peripheral blood lymphocytes. Furthermore, 74 melanoma patients were 
      typed for HLA class II by high-resolution sequence specific primer-polymerase 
      chain reaction. Response rate and treatment-related toxicity in those patients 
      receiving IL-2-based treatment (N = 272) were compared with HLA serologic types. 
      The frequency of four HLA-B alleles was significantly different in the melanoma 
      compared with the NAC population: of these, HLA-B5, -B8, and -B15 had a frequency 
      falling between the NAC and the Northern European population. No other 
      significant differences between melanoma patients and NAC population were noted 
      for other HLA loci. A correlation was noted between HLA-DR3 and -DR4 alleles and 
      decreased tolerance to IL-2, whereas homozygosity for HLA-DR decreased the chance 
      of response. There were no significant associations between HLA type and 
      response. It is unlikely that the associations noted between some HLA-B alleles 
      and melanoma bear significantly on the etiology of the disease. The differences 
      seen between American melanoma patients and the NAC population are probably best 
      explained by geographical ancestry. The association between HLA-DR and tolerance 
      to IL-2 therapy noted in this study may offer insight toward the understanding of 
      mechanisms regulating the cascade of events after the systemic administration of 
      IL-2.
FAU - Marincola, F M
AU  - Marincola FM
AD  - Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892, USA.
FAU - Shamamian, P
AU  - Shamamian P
FAU - Rivoltini, L
AU  - Rivoltini L
FAU - Salgaller, M
AU  - Salgaller M
FAU - Cormier, J
AU  - Cormier J
FAU - Restifo, N P
AU  - Restifo NP
FAU - Simonis, T B
AU  - Simonis TB
FAU - Venzon, D
AU  - Venzon D
FAU - White, D E
AU  - White DE
FAU - Parkinson, D R
AU  - Parkinson DR
LA  - eng
GR  - NIH0010139353/ImNIH/Intramural NIH HHS/United States
GR  - Z01 BC010763-01/ImNIH/Intramural NIH HHS/United States
GR  - Z99 TW999999/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - J Immunother Emphasis Tumor Immunol
JT  - Journal of immunotherapy with emphasis on tumor immunology : official journal of 
      the Society for Biological Therapy
JID - 9418950
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Interleukin-2)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
CIN - J Immunother Emphasis Tumor Immunol. 1996 Sep;19(5):381-5. PMID: 8941878
MH  - Gene Frequency
MH  - HLA Antigens/*genetics/*immunology
MH  - HLA-DR Antigens/genetics/immunology
MH  - Histocompatibility Testing
MH  - Humans
MH  - Immunophenotyping
MH  - Interleukin-2/therapeutic use
MH  - Melanoma/*genetics/*immunology/therapy
MH  - Prospective Studies
MH  - Tumor Necrosis Factor-alpha/biosynthesis
PMC - PMC2562232
MID - NIHMS65802
EDAT- 1995/11/01 00:00
MHDA- 1995/11/01 00:01
PMCR- 2008/10/06
CRDT- 1995/11/01 00:00
PHST- 1995/11/01 00:00 [pubmed]
PHST- 1995/11/01 00:01 [medline]
PHST- 1995/11/01 00:00 [entrez]
PHST- 2008/10/06 00:00 [pmc-release]
AID - 10.1097/00002371-199511000-00005 [doi]
PST - ppublish
SO  - J Immunother Emphasis Tumor Immunol. 1995 Nov;18(4):242-52. doi: 
      10.1097/00002371-199511000-00005.